StockMarketWire.com - Data science company Ixico said Thursday it had signed a further change order to a current contract with a biopharmaceutical company, increasing the total contract value to €1.3m.

The latest amendment results in a total change in the contract value of €0.5m or 65% above the original value of €0.8m, the company said.

The change order reflected an extension of the contract term from September 2020 to May 2021 and the addition of new clinical sites, the company said.

'We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes,' said Giulio Cerroni, Chief Executive Officer of IXICO.




At 8:45am: [LON:IXI] IXICO plc share price was 0p at 30.5p



Story provided by StockMarketWire.com